Collectively, these results demonstrate that 67NR–derived CD19+ B cells inhibited multiple hallmarks of bone metastatic disease, including T cell–mediated RANKL production, tumor-induced bone resorption, and colonization of skeletal tissues, reinforcing their role as negative regulators of bone metastatic disease in vivo. Here, CD19 is linked to neoplasm.